Related Experiment Videos
Anti-apoptotic oncogenes prevent caspase-dependent and independent commitment for cell death
G P Amarante-Mendes1, D M Finucane, S J Martin
1Division of Cellular Immunology, La Jolla Institute for Allergy and Immunology, 10355 Science Center Dr., San Diego, California 92121, USA.
Cell Death and Differentiation
|April 14, 1999
Summary
Blocking caspases prevents apoptosis but not cell death, indicating oncogenesis involves an earlier commitment point. This research explores cell death pathways and cancer development.
Area of Science:
- Cell Biology
- Molecular Biology
- Oncology
Background:
- Apoptosis, or programmed cell death, is regulated by caspases and implicated in cancer.
- Resistance to apoptosis is a key factor in oncogenesis.
Purpose of the Study:
- To investigate the role of caspases in cell death and oncogenesis.
- To determine if inhibiting caspases prevents cell death and preserves cell viability.
Main Methods:
- Used a broad-spectrum caspase inhibitor (zVAD-fmk) to block apoptosis.
- Induced apoptosis using anti-CD95 mAb, staurosporine, VP-16, and Act-D.
- Assessed cell death morphology, biochemical changes, and clonogenic potential.
Main Results:
- zVAD-fmk inhibited apoptosis but did not prevent cell death induced by staurosporine, VP-16, or Act-D.
- Cells treated with these drugs lost clonogenic potential despite caspase inhibition.
- Alternative cell death pathways involving vacuolization and membrane damage were observed.
- Overexpression of anti-apoptotic genes (bcl-2, bcr-abl) inhibited apoptosis and preserved clonogenic potential.
Conclusions:
- Blocking caspase-mediated apoptosis alone does not prevent cell death or rescue clonogenic potential.
- Oncogenesis is promoted by preventing an earlier event, termed the commitment point for cell death.
- Understanding this commitment point is crucial for cancer development research.